Quick Answer
Indaptus Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $8.51 million for the year ending 2025.
- Indaptus Therapeutics, Inc. showed an increase of +47.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Indaptus Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $13.80 million | Q2 2021: $16.99 million | Q3 2021: $41.86 million | Q1 2022: $33.22 million | Q2 2022: $14.26 million | Q3 2022: $6.72 million | Q1 2023: $6.81 million | Q2 2023: $12.70 million | Q3 2023: $15.96 million | Q1 2024: $9.74 million | Q2 2024: $7.30 million | Q3 2024: $7.38 million | Q1 2025: $3.89 million | Q2 2025: $6.16 million | Q3 2025: $5.83 million.
- Over the full 6 years of available data (2020 to 2025), Indaptus Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 419.6%.
- Historical annual values: Fiscal year 2025: $8.51 million | Fiscal year 2024: $5.79 million | Fiscal year 2023: $13.36 million | Fiscal year 2022: $9.63 million | Fiscal year 2021: $39.13 million | Fiscal year 2020: $1.64 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: